Foster City

BioPharma, Pharma

Gilead Sciences Gets a Shot at Next-Gen Cell Therapy With $325M Arcellx Alliance

In partnering with clinical-stage Arcellx, Gilead Sciences gains the opportunity to develop a cell therapy for multiple myeloma that could offer advantages over currently available therapies for the blood cancer. The deal announced Friday came as Arcellx reported additional data during the annual meeting of the American Society of Hematology that showed continued durability of the cell therapy. 

BioPharma, Pharma

Gilead claims breast cancer trial win but offers few details; drug application is filed with FDA

Gilead Sciences said it has statistically significant and clinically meaningful data from a pivotal test of its cancer drug, Trodelvy, in the most common type of breast cancer. While detailed data remain undisclosed, the company said it has filed a submission with the FDA seeking to expand the drug’s approval to include this larger group of breast cancer patients.